Table 1.
Clinical and demographic information of the ICICLE-GAIT cohort at 18-, 36-, 54-, and 72-months assessment timepoints
| 18 months | 36 months | 54 months | 72 months | |||||
| Group | PD | OA | PD | OA | PD | OA | PD | OA |
| n | 43 | 51 | 62 | 94 | 59 | 49 | 49 | 43 |
| Age (y) | 69±10 | 70±7 | 69±10 | 72±6 | 68±9 | 73±8 | 71±9 | 72±6 |
| Sex (Male / Female) | 31 / 12 | 27 / 24 | 40 / 22 | 44 / 50 | 39 / 20 | 28 / 24 | 35 / 14 | 26 / 17 |
| Height (meters) | 1.69±0.88 | 1.69±0.08 | 1.69±0.08 | 1.68±0.09 | 1.68±0.8 | 1.70±0.09 | 1.67±0.09 | 1.70±0.08 |
| Body Mass (kg) | 79±15 | 81±15 | 79±17 | 77±13 | 76±15 | 81±13 | 77±14* | 84±13 |
| MDS-UPDRS III (points) | 33±11 | - | 38±12.4 | - | 39.1±12.6 | - | 40.9±13.8 | - |
| Disease duration (y) | 7.90±4.69 | - | 8.77±4.02 | - | 10.36±4.31 | - | 12.01±4.5 | - |
| Hoehn and Yahr Stage | ||||||||
| I, n (%) | 5 (11%) | - | 1 (1%) | - | 1 (2%) | - | 0 (0%) | - |
| II, n (%) | 40 (85%) | - | 57 (90%) | - | 51 (86%) | - | 35 (70%) | - |
| III, n (%) | 2 (4%) | - | 6 (9%) | - | 7 (12%) | - | 12 (24%) | - |
| IV, n (%) | 0 (0%) | - | 0 (0%) | - | 0 (0%) | - | 3 (6%) | - |
| LEDD (mg/day) | 395±206 | - | 515±256 | - | 663±294 | - | 720±312 | - |
Data presented as mean±standard deviation. Bold highlight indicates significant difference between PD and OAs at specific time point. ‘-‘describes an empty field, due to data availability. MDS-UPDRS III = Movement Disorder Society – Unified Parkinson’s Disease Rating Scale – Part III. LEDD = Levodopa equivalent daily dosage.